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Abstract  
 
The process of cellular senescence generates a repressive chromatin environment, however, the role 
of histone variants and histone proteolytic cleavage in senescence remains unclear. Using models of 
oncogene-induced and replicative senescence, we have identified novel histone H3 tail cleavage 
events mediated by the protease Cathepsin L. We find that cleaved forms of H3 are nucleosomal and 
the histone variant H3.3 is the preferred cleaved form of H3. Ectopic expression of H3.3 and its 
cleavage product (H3.3cs1), which lacks the first twenty-one amino acids of the H3 tail, is sufficient to 
induce senescence. Further, H3.3cs1 chromatin incorporation is mediated by the HUCA histone 
chaperone complex. Genome-wide transcriptional profiling revealed that H3.3cs1 facilitates 
transcriptional silencing of cell cycle regulators including RB/E2F target genes, likely via the permanent 
removal of H3K4me3. Collectively, our study identifies histone H3.3 and its proteolytically processed 
forms as key regulators of cellular senescence. 
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Cellular senescence is a stable form of growth arrest and is thought to function as a potent anti-tumor 
mechanism1,2. Cellular senescence was originally defined as ‘replicative exhaustion’ that occurs in 
cultured cells over time, but can also be provoked prematurely by stresses that include DNA damage 
and activated oncogenes3-5. For example, melanocytes within human nevi often harbor an activating 
mutation in BRAF (BRAFV600E) and can remain senescent for decades6. Characteristic features of 
senescent cells include morphological and physiological alterations, senescence-associated -
galactosidase (SA--gal) activity, chromatin condensation and extensive gene expression changes4,7. 
 
Senescence is mediated by the RB and p53 pathways, which cooperate to ensure cell cycle inhibition7-
9. A growing body of evidence suggests that the process of cellular senescence is also mediated by 
chromatin changes10-15. Notably, senescent human cells often accumulate distinct DAPI-dense nuclear 
foci known as senescent-associated heterochromatin foci (SAHFs). SAHFs are enriched for repressive 
chromatin modifications such as H3K9me3 and H3K27me3, chromatin architectural factors like HMGA 
proteins, and the histone variant macroH2A11-13. Interestingly, SAHF formation is not driven by a 
redistribution of histone post-translational modifications (PTMs) in the senescent genome, but rather a 
spatial reorganization of existing repressive PTMs14. The deposition of macroH2A is a late step in 
SAHF formation and is dependent on components of the H3.3 histone chaperone complex HUCA 
(HIRA/UBN1/CABIN1/ASF1a)12. Interestingly, ectopic expression of HIRA or ASF1a alone or together 
can induce senescence, however the role of H3.3 in driving a senescence program remains unclear. 
 
Recently, we mapped the histone PTM profile of senescent cells15. We identified a striking loss of 
H3K4me3, a PTM associated with active transcription, at E2F target genes. We further identified the 
H3K4 demethylases JARID1A and JARID1B to be responsible for the removal of H3K4me3. In addition 
to the action of histone modifying enzymes, the incorporation of histone variants and the proteolytic 
processing of histones have also emerged as mechanisms that alter the histone PTM landscape16. In 
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fact, proteolytic processing of histone H3 has been reported in the heterochromatic micronuclei of 
Tetrahymena17 and during embryonic stem cell (ESC) differentiation via the lysosomal protease 
Cathepsin L1 (CSTL1)18. However, a clear biological function for such histone tail processing has yet to 
be elucidated.  
 
In this study, we report evidence of H3 tail proteolytic processing in models of both oncogene-induced 
and replicative senescence. We identified two distinct processing sites of the H3 tail, both of which are 
mediated by CTSL1. One of these sites, H3cs1, corresponds to the cleavage site identified in 
differentiating ESCs, which generates a new H3 tail beginning at amino acid T2218. We find a 
chromatin-bound pool of the active CTSL1 protease, which correlates with the emergence of cleaved 
H3 products during senescence. We demonstrate that the histone variant H3.3 is cleaved during 
senescence and that ectopic expression of H3.3, and to a greater extent H3.3cs1, induces senescence 
in the absence of oncogenic signaling. Further, the chromatin incorporation of endogenous cleaved H3 
during oncogene-induced senescence (OIS) and ectopic H3.3cs1 requires the HUCA complex. RNA-
sequencing (RNA-seq) studies revealed that introduction of H3.3cs1 into primary fibroblasts results in 
rapid transcriptional downregulation of cell cycle genes, with significant overlap of those downregulated 
during OIS. H3.3cs1 downregulated genes also significantly overlap with genes that lose H3K4me3 
during senescence, many of which are RB and JARID1A/1B targets15. Together, these findings suggest 
that H3 tail cleavage functions as a key mechanism to remove H3K4me3, and thereby contributes to 
the silencing of cell cycle-promoting genes during senescence.  
 
Results 
Senescent fibroblasts exhibit nucleosomal species of processed histone H3  
RAS-induced senescence (ER::H-RASG12V) in IMR90 fibroblasts is a well-characterized system in which 
senescence is enforced by the combined action of the RB and p53 tumor suppressor pathways9,19. 
Using this system, we induced senescence by addition of 4-hydroxytamoxifen (4OHT) to primary 
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fibroblasts and assayed cells for established senescence markers (Figure 1a; Supplementary Figure 
S1). Consistent with our previous findings15, we detected a striking loss of H3K4me3 during 
senescence (Figure 1b). Upon immunoblotting for histone PTMs such as H3K14 and H3K18 
acetylation, we noted not only an expected decrease of these marks, but also a faster running species 
of H3 (Figure 1b, asterisks). Immunoblotting of PTMs more distal in the tail (H3K27me3 or H3K36me3) 
or with a C-terminal H3 antibody, revealed an additional faster migrating species of H3 (Figure 1b, 
arrows). These faster-migrating species appeared with increasing intensity over a senescence time 
course of approximately two weeks, but were not detected with antibodies specific for PTMs at the N-
terminus of the H3 tail such as H3K4me3 and H3K9me3. No evidence of H4 cleavage was detected 
either (Figure 1b). Collectively, these results suggested that the N-terminal tail of H3 is specifically 
cleaved during OIS at two distinct sites.  
 
Using a combination of histone PTM-specific antibodies and an H3 cleavage-specific antibody (α
H3cs1;18), we aligned the putative cleavage sites of the H3 tail (Figure 1c). Because the H3K14ac 
antibody detects a faster migrating band that is not detectable with the H3K9me3 antibody, the proximal 
cleavage site most likely lies at or within the K9-K14 stretch (see Figure 1d). The distal cleavage site 
aligns with the H3cs1 antibody, which was designed to recognize H3 with a N-terminus beginning at 
T22 (Figure 1c,d; H3cs1 epitope: TKAAR18). Therefore, we refer to the distal cleavage site as H3cs1 
and the proximal site as H3cs2 (Figure 1d). Due to our ability to probe H3cs1 with a specific antibody, 
we focused our studies on this distal cleavage site. Levels of H3cs1 dramatically increase upon OIS 
(Figure 1e) and appear at much higher levels in senescent cells than mouse ESCs induced to 
differentiate (Supplementary Figure S2).  
 
We next investigated if the cleaved H3 species were incorporated into chromatin and more specifically, 
nucleosomes. Growing and senescent IMR90s were fractionated into chromatin-free and chromatin 
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fractions and probed with antibodies against H3cs1 and the C-terminal region of H3. Cleaved H3 
products were detected only in the chromatin fraction of senescent cells (Figure 1f). Next, soluble 
mononucleosomes were isolated from growing and senescent fibroblasts and immunoblotting revealed 
that cleaved H3 species are indeed nucleosomal in senescent cells (Figure 1g). We highlight here that 
cleaved forms of the replication-independent histone variant H3.3 were also detected in these assays, 
suggesting that this histone variant may be preferentially processed in senescent cells (see below). 
 
Senescent melanocytes harbor chromatin-bound processed forms of H3  
We also investigated chromatin changes in human primary melanocytes induced to senesce. These 
specialized pigment cells can remain senescent in human nevi (moles) for decades, and have the 
potential to progress into melanoma. We induced senescence via serial passaging of melanocytes 
(replicative senescence) and using the activated oncogene BRAFV600E (OIS)6. Senescence was 
monitored via multiple established assays (Supplementary Figure S3a-c). As evidenced in Figure 1h, 
the histone H3 tail is cleaved during both modes of senescence in primary human melanocytes. 
Interestingly, the same pattern of processing observed in fibroblasts is detected in melanocytes, and 
the fastest migrating species corresponds to H3cs1 (Figure 1h). Like fibroblasts, the cleaved forms of 
H3 in senescent melanocytes are chromatin-associated (Supplementary Figure 3d).  
 
Next, we queried whether H3cs1 could be a marker of senescence in vivo by probing acid-extracted 
histones isolated from fresh frozen benign nevi for H3cs1. We identified the presence of H3cs1 in the 
majority of benign nevi samples tested (5/7), but not growing primary melanocytes (Figure 1i). Further, 
by probing a panel of melanoma cell lines, we found that metastatic melanoma cells lack H3cs1, while 
primary melanoma lines that fail to proliferate in culture contain H3cs1 (Supplementary Figure S3e). 
These finding suggests that H3cs1 may be a useful marker for assessing senescence in premalignant 
lesions.  
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Processing of H3 requires activation of senescence effector pathways 
We questioned whether oncogene activation or DNA damage, in the absence of senescence, could 
trigger H3 cleavage. First, we examined cells subjected to oncogenic stress but unable to undergo 
senescence. E1A-transduced ER::H-RASG12V IMR90s induced with 4OHT failed to enter senescence 
(Supplementary Figure S4a, b), and were defective in H3 tail cleavage after 6 days of RASG12V 
activation (Supplementary Figure S4c). Moreover, acute induction of DNA damage via 24 hours of 
etoposide treatment in IMR90s was not sufficient to induce H3 tail cleavage either (Supplementary 
Figure S4d). Here, fibroblasts were arrested but not senescent as evidenced by various markers, 
including a lack of p16 expression (Supplementary Figure S4d, e). These results strongly suggest that 
engagement of senescence effector pathways is required for the processing of H3.   
 
Cathepsin L cleaves the H3 tail and its inhibition impairs SAHF formation 
The lysosomal protease CTSL1 localizes to the nucleus upon RAS activation20 and is responsible for 
cleaving the nuclear transcription factor CDP/Cux and the H3 tail18,21. In order to investigate whether 
CTSL1 is responsible for H3 tail cleavage during senescence, we first probed the levels of CTSL1 upon 
senescence induction in fibroblasts and melanocytes. CTSL1 levels increase transcriptionally and more 
strikingly at the protein level upon senescence in both systems (Figure 2a-c). CTSL1 is found in three 
forms: the pro-cathepsin, intermediate and processed mature (active) forms22. Interestingly, our data 
shows that the chromatin-bound pool of CTSL1 is enriched in the mature, active form of the protease, 
consistent with previous findings18. For example, at day four of senescence induction, only ~17% of 
CTSL1 exists in its mature form (Figure 2a) while the chromatin-bound levels comprise ~40% (Figure 
2b). In senescent melanocytes, we could only detect the mature form of CTSL1 in the chromatin 
fraction (Figure 2c). Finally, a detailed time course analysis of the early stages of senescence in 
IMR90s demonstrates that CTSL1 mRNA expression correlates with detection of active CTSL1 in the 
chromatin fraction, precisely when H3 tail cleavage is observed (Figure 2b).  
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Next, we used both chemical inhibition (CTSLi) and shRNA approaches to assess the role of CTSL1 in 
processing the H3 tail. IMR90 ER::RASV12 cells were induced to senesce with 4OHT in the presence of 
either DMSO or a potent irreversible CTSL1-specific inhibitor (Figure 2d). This inhibitor blocks self-
processing of CTSL1 into its mature form, leading to the accumulation of the intermediate form 
(Supplementary Figure S5a). Additionally, ER::RASV12 infected fibroblasts were engineered to express 
either shCTSL1 or shLuc control. This knock down was specific for CTSL1 and was maintained over a 
two-week course of senescence (Supplementary Figure S5). In both scenarios, when cells were 
induced to senesce, we observed a block in the production of both H3cs1 and cs2 (Figure 2d, 2e). This 
implicates CTSL1 as the key protease responsible for the observed cleavage events. Of note, we 
observed that loss of H3K4me3 is less pronounced upon CTSL inhibition as compared to DMSO 
treated cells (Figure 2d, and see below).  
 
Next we queried if CTSL1 inhibition, and thus a block in H3 cleavage, could bypass OIS. The inhibition 
of CTSL did not allow for increased proliferation in IMR90 ER::RASV12 cells induced to senesce 
(Supplementary Figure S6), however its inhibition/deficiency significantly impaired SAHF formation 
(Figure 2f). While these data show that CTSL1 inhibition alone is not sufficient to bypass a robust 
senescence system like RASV12-driven OIS in IMR90s, they do suggest that CTSL1 activity and its 
downstream substrates (H3 and possibly others) are important for SAHF formation.  
 
H3.3 and H3.3cs1 induce a senescence program 
Canonical H3.1 and the variant H3.3 differ by only five amino acids. Four of these residues cluster in 
the interface between H3.3 and H4, a region that mediates the interaction with distinct histone 
chaperone complexes23. The other differential amino acid is at position 31, which resides in the histone 
tail (Figure 1d). In order to assess which H3 isoform is proteolytically processed during senescence, we 
first probed the chromatin fraction of growing and senescent cells with an antibody against H3.3 (which 
recognizes the C-terminus of the histone). We verified this antibody is specific for H3.3 by 
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immunoblotting tagged forms of H3.1 and H3.3 (Supplementary Figure S7a). Using this antibody, we 
detected H3.3 cleavage products in senescent fibroblasts and melanocytes (Figures 1f and 
Supplementary Figure S4d). Moreover, H3.3 and its cleavage products are incorporated into 
nucleosomes (Figure 1g). As previously reported10, we also find increased levels of H3.3 during a 
senescence time course (Supplementary Figure S7b). 
 
Next, we inquired whether ectopic expression of full-length forms of Flag-tagged H3.1 (H3.1FL) and 
H3.3 (H3.3FL) could induce senescence in IMR90s. As expected, these ectopically expressed histones 
are localized to the nucleus by immunofluorescence (Supplementary Figure S7c). Intriguingly, by 
immunoblotting for Flag, we observed that H3.3 is cleaved with a similar pattern to that of OIS (Figure 
3a, b). Because of this finding, we next inquired if expression of H3.3FL or H3.3cs1 was sufficient to 
induce senescence in IMR90s in the absence of oncogenic signaling. Thus, we generated H3.3cs1-
Flag, which co-migrates with the faster migrating band of H3.3FL-Flag cleavage products (Figure 3b). 
Further supporting our investigation of H3.3cs1 in senescence, the identical construct generated for 
H3.1 (H3.1cs1) was not expressed or incorporated into chromatin (Supplementary Figure S7c, d), 
suggesting that histone chaperone recognition was compromised or that this form of H3.1 may not be 
physiologically relevant. 
 
Through a rigorous series of experiments, we found that H3.3cs1 induces senescence in fibroblasts 
compared to empty vector control (pBabe) and H3.1FL. Importantly, ectopic H3.3cs1 is expressed at 
similar levels to that of endogenous H3cs1 during OIS (Supplementary Figure S8a). H3.3FL can also 
induce senescence, albeit in a less robust manner than H3.3cs1. Senescence induction in this system 
was monitored by cell morphology and SA-β-gal staining (Figure 3c), incorporation of EdU to assess 
DNA replication (Figure 3d), expression of CCNA (Cyclin A2), p16, p21 (Supplementary Figure S8b-d), 
and SAHF formation (Figure 3e). Consistent with a senescent phenotype, cells expressing H3.3FL and 
H3.3cs1 showed larger nuclei than those expressing H3.1FL or pBabe (Figure 3f, top panel). At higher 
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magnification, DAPI-dense SAHFs were clearly observed only in H3.3FL and H3.3cs1 expressing 
fibroblasts (Figure 3f). Moreover, these SAHFs stained positively for macroH2A1, a late marker of 
SAHF formation12, suggestive of established SAHFs (Figure 3f). Further, we find that H3.3FL and 
H3.3cs1 induce heterochromatization as evidenced by increased resistance to digestion with 
micrococcal nuclease (Figure 3g) and changes in the PTM and histone variant profile consistent with 
senescence, including increased H4K20me3 and macroH2A levels (Figure 3h).  
 
Next we questioned whether H3.3L20A, a mutation of H3 that prevents CTSL1-mediated cleavage24, 
would induce senescence. Colony formation assays (Figure 3i), quantitation of SA-β-gal staining and 
incorporation of EdU (Supplementary Figure S9) showed that L20A induces a senescence phenotype 
similar to that of wild type H3.3FL. These findings suggest that full-length H3.3 indeed plays a role in 
senescence independent of its proteolytic processing, which is not unexpected as senescent cells rely 
on DNA replication-independent incorporation of histone H3.3 as they exit the cell cycle25. Taken 
together, these results provide evidence that the predominant form of H3 proteolytically processed by 
CTSL1 during senescence is H3.3. Moreover, they demonstrate that H3.3 and more robustly its 
cleaved product (H3.3cs1), but not H3.1, can drive a cellular senescence program.  
 
The histone chaperone complex HUCA is required for chromatin incorporation of H3.3cs1 
Next, we examined the localization of Flag-tagged H3.3FL and H3.3cs1 in IMR90s. H3.3FL and 
H3.3cs1 were found largely excluded from SAHF, which were marked by H3K9me3 (Figure 4a). This is 
consistent with a recent study that also showed exclusion of H3.3 from SAHF25. These data further 
suggest that cleavage of H3.3 does not compromise H3K9me3, which is likely to be found on canonical 
H3.1 or H3.2 in SAHF. 
 
Because the ectopic expression of H3.3FL and H3.3cs1 demonstrated a largely euchromatic nuclear 
localization (Figure 4a), we hypothesized that the HUCA histone chaperone complex may be 
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responsible for H3.3cs1 deposition in senescent cells. The HUCA histone chaperone complex interacts 
specifically with H3.3, and is responsible for its deposition at distinct chromatin regions, including 
transcription start sites and the bodies of active genes26,27. In order to test if this complex is required for 
chromatin incorporation of endogenous H3cs1 during OIS senescence, IMR90 ER::RASV12 cells were 
infected with lentiviral shRNAs against HIRA, ASF1a, UBN1 or luciferase control and induced to 
senescence. During the course of these studies, we noted that the HIRA knockdown was reproducibly 
incompatible with cell viability, and we therefore focused on knock down of ASF1a and UBN1. Upon 
knockdown of either ASF1a or UBN1 (Figure 4b, Supplementary Figure S10a), we observed a dramatic 
reduction in the incorporation of H3cs1 in the chromatin fraction compared to control cells (Figure 4c). 
This was specific for HUCA, as knockdown of Daxx, a component of a separate chaperone that 
deposits H3.3 at telomeres28,29, did not affect H3cs1 levels in chromatin (Supplementary Figure S10b, 
c). 
 
To complement these findings, we investigated whether ASF1a mediates the ability of ectopically 
expressed H3.3cs1 to induce senescence in IMR90s in the absence of oncogenic signaling. We 
generated an H3.3cs1-Flag construct with an R to E substitution at position 129 (R129E), a mutation 
that has been shown to disrupt interaction of H3.3 with ASF1a23. We also generated H3.3cs1-Flag 
containing an S to A substitution at position 31 (S31A), which mimics the tail of H3.1 and is not likely to 
alter chaperone binding. IMR90 cells were transduced with pBabe, H3.3cs1, H3.3cs1 S31A, and 
H3.3cs1 R129E (Figure 4d). Immunoblots with α-Flag demonstrate that while H3.3cs1 and H3.3cs1 
S31A are incorporated into chromatin, H3.3 R129E is not (Figure 4d). Consistent with these findings, 
H3.3cs1 S31A induces senescence as efficiently as H3.3cs1, as measured by changes in cell 
morphology and increased SA-β-gal staining (Figure 4e), loss of EdU incorporation (Figure 4f), 
induction of SAHF formation (Figure 4G), decreased CCNA expression (Figure 4h), and induction of 
p16 (Figure 4i). On the other hand, H3.3cs1 R129E failed to induce senescence markers in IMR90 cells 
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by all accounts (Figure 4e-i). Collectively, these data suggest that ASF1a and UBN1, via direct 
interaction with H3.3, are required for incorporation of cleaved H3.3 into chromatin.  
 
H3.3cs1 contributes to the transcriptional repression of cell cycle-promoting genes 
To gain a better understanding of the gene expression program mediated by cleaved H3.3, we 
performed RNA-seq of growing and OIS fibroblasts, as well as fibroblasts expressing H3.3cs1 at two 
different time points post-infection (early; day 3 and late; day 13). As expected, we found a dramatic 
change in the gene expression program of OIS as compared to growing cells (Figure 5a; 
Supplementary Table 1). Interestingly, we noted that the majority of the differentially expressed genes 
in the H3.3cs1-induced senescence samples at both early and late time points were downregulated 
when compared to growing cells. We found a striking significant overlap between these downregulated 
genes and genes downregulated in OIS (Figure 5a, 5b), suggesting that similar pathways are 
repressed in both systems. Consistent with our previous findings15, Gene Ontology (GO) analysis 
reveals that OIS and H3.3cs1 downregulated genes are similarly involved in cell cycle progression 
(Supplementary Figure S11a). In order to understand transcription factor enrichment for the 
differentially expressed downregulated genes during both OIS and H3.3cs1-induced senescence, we 
used the ChIP-X Enrichment Analysis tool (ChEA), which contains gene lists for 205 different 
mammalian transcription factors extracted from over 230 ChIP-Seq or ChIP-chip publications30. This 
analysis confirms that these downregulated genes are targets of a common set of transcription factors 
and epigenetic regulators, including members of the E2F family and the H3K4me3 demethylase 
KDM5B (JARID1B) (Figure 5c).  
 
Previously, we reported that RB and JARID1A/1B cooperate in the silencing of E2F targets during 
senescence via H3K4me3 demethylation15. To investigate a potential role for H3 tail cleavage in the 
removal of H3K4me3, we compared our RNA-seq results to the ChIP-seq and gene expression data 
from that study. We found a significant overlap between H3.3cs1-downregulated genes and those 
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genes in which H3K4me3 is lost during senescence (Figure 5d, left). Furthermore, the overlap between 
H3.3cs1 downregulated genes and those regulated by JARID1A/1B (Figure 5d, right) and RB 
(Supplementary Figure S11b) is highly significant.  
 
Next, we performed ChIP for H3K4me3 in IMR90s expressing either H3.1FL (which does not induce 
senescence) or H3.3cs1 (which induces senescence). We focused on the promoters of representative 
cell cycle-promoting genes, senescence-associated secretory phenotype-related genes (see below), 
GAPDH (not transcriptionally altered upon senescence), as well as intergenic regions that are not 
occupied by H3K4me3 as negative controls (Figure 5e). We found that cell cycle genes that are 
transcriptionally downregulated during H3.3cs1-induced senescence (via RNA-seq) show significantly 
less H3K4me3 at their promoters as compared to H3.1FL-expressing cells. Of note, these 
representative genes are also downregulated in OIS, but are not reported targets of the JARID1A/1B 
demethylases15. Together, these data support a model in which H3.3 tail cleavage functions in a similar 
manner as the JARID1 demethylases to remove H3K4me3 and facilitate silencing of proliferation-
promoting RB/E2F target genes during senescence (Figure 5e). It further suggests that the proteolytic 
processing of the H3.3 tail functions as a key mechanism for H3K4me3 loss at a subset of genes that 
are downregulated during senescence. This is supported by the fact that CTSL inhibition partially 
impedes the loss of H3K4me3 in senescent cells (Figure 2d, top blot).  
 
Finally, we observed that a much larger set of genes is upregulated during OIS than during H3.3cs1-
induced senescence (early and late) compared to growing cells (Figure 5a), and that there is little 
overlap between these groups (Figure 5b, bottom). GO analysis of the upregulated genes in each 
system reveals that in fact different biological processes are affected (Supplementary Figure S11c, d). 
Fibroblasts undergoing OIS display induction of cell signaling, inflammatory and secretory pathways 
that play a major role in the senescence-associated secretory phenotype (SASP)7,31,32. This includes 
IL6, IL8, MMP3, CXCL1, among others (see Supplementary Table 1). Interestingly, H3.3cs1-induced 
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senescence appears largely deficient in SASP induction, which may explain in part the milder 
senescence phenotype observed as compared to RASV12-induced senescence. We note however that 
some SASP-like factors such as IGFBP2, 3, 7 and TGFβ2 were induced upon H3.3cs1 ectopic 
expression. While heterogeneous in nature, multiple lines of evidence suggest that a persistent DNA 
damage response is required to trigger SASP32,33. Consistent with this, we found that while OIS triggers 
a DNA-damage response as previously reported34,35, H3.3cs1 overexpression fails to do so 
(Supplementary Figure S12).  
 
Discussion 
Although senescence is associated with dramatic reorganization of chromatin structure, the distinct 
mechanistic chromatin-mediated events that contribute to this process remain poorly understood. Here 
we uncover novel senescence-associated proteolytic processing of histone H3 mediated by CTSL1 in 
human fibroblasts and melanocytes. CTSL1 cleaves the histone H3 tail at least at two distinct sites 
generating new N-termini at residues T22 (H3cs1), as previously reported in differentiating mouse 
ESCs18, and a novel site likely between K9 and K14 (H3cs2). Of note, H3cs2 was not identified in ESCs 
upon differentiation18, and thus appears specific for cellular senescence. It will be of interest in the 
future to map the precise N-terminus of H3cs2, determine if the cs1 and cs2 cleavage events occur 
sequentially or simultaneously, and to investigate whether H3cs2 can also induce senescence. 
 
Recently, a study reported evidence of senescence-associated H3 tail cleavage, however this was 
reported to be a cytoplasmic event36. In that study, H3 tail processing was due to chromatin fragments 
budding out of the nucleus as a consequence of disrupted nuclear envelope integrity. In turn, histones 
could be processed by lysosomes and progressively depleted. We have no evidence to suggest 
cytoplasmic processing of H3 in our systems and demonstrate that cleaved forms of H3 are indeed 
associated with chromatin and incorporated into nucleosomes. Moreover, the presence of active 
CTSL1 in the chromatin fraction of senescent cells is consistent with findings from other 
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systems18,20,21,37. However, it remains plausible that a small fraction of cytoplasmic H3cs1 was not 
detectable by our biochemical methods or that the appearance of such cytoplasmic histone processing 
occurs at later time points of senescence than we have assayed.  
 
Because H3.3 is deposited into chromatin in a DNA replication-independent manner, it is likely that 
non-dividing cells, like those undergoing senescence, depend on incorporation of H3.3. In fact, a recent 
study shows that while newly synthesized H3.3 is actively deposited into chromatin of senescent cells, 
H3.1 is not25. Consistent with this idea, we and others have found increased levels of H3.3 in the 
chromatin template of senescent cells (Supplementary Figure S7b; reviewed in10). We also found that 
the ectopic expression of H3.3, but not H3.1, induces a senescence program in fibroblasts 
characterized by classic markers of bona fide senescence, including increased SA-β-Gal activity and 
formation of macroH2A-containing SAHF (Figure 3). The observed senescence phenotype is more 
robust with cleaved H3.3 (H3.3cs1) than the full-length histone, suggesting that the proteolytic 
processing of H3.3 is particularly important.  
 
The fact that the ASF1a and UBN1 are required for the chromatin incorporation of H3cs1 during 
senescence is consistent with studies reporting a role for HIRA and ASF1a in senescence12. We further 
demonstrate that the ability of ectopic H3.3cs1 to induce senescence is dependent on its ability to 
directly interact with ASF1a (Figure 4). Because HIRA knockdown is incompatible with fibroblast 
viability, we cannot exclude a role for HIRA in H3.3cs1 deposition, and suggest that it may play distinct 
roles in proliferating versus senescent cells. Interestingly, while histone chaperone complexes have 
preferred histone targets (e.g. HUCA with H3.3 and HJURP with CENPA), evidence to date suggests 
that upon altered cellular conditions, alternate chaperone complexes can deposit histones if the 
preferred factor is not available or the histone is overexpressed27,28,38. However, our data suggests that 
HUCA is unique in its ability to incorporate H3.3cs1 into chromatin, as other chaperones could not 
compensate in its absence or for a disruption of the H3.3-ASF1a interaction in IMR90 cells.  
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While HUCA components HIRA and ASF1a have been implicated in regulating senescence12,39, our 
studies suggest for the first time that their substrate H3.3, as well as its nucleosome-incorporated 
cleaved product H3.3cs1, play an important role in promoting senescence. Consistent with data from 
others25, our immunofluorescence data suggests that H3.3 is largely excluded from SAHF. Interestingly, 
we also show that CTSL1 inhibition/knockdown leads to defective SAHF formation during OIS, raising 
the possibility that H3 tail cleavage may play a role in the reorganization of chromatin during 
senescence.  
 
Here, we provide evidence that H3.3cs1 can mediate gene expression pathways consistent with 
senescence. Specifically, we found that H3.3cs1 mediates the transcriptional repression of a large 
subset of genes previously shown to be downregulated by RB and JARID1A/1B during senescence15. 
Like RB and JARID1 regulated genes, a large subset of H3.3cs1 downregulated genes lose H3K4me3 
and are primarily E2F targets involved in cell cycle progression. We find that such transcriptional 
suppression occurs even at very early time points after introduction of H3.3cs1 (e.g. three days; Figure 
5a,b), and is coupled to a lack of H3K4me3 promoter occupancy (Figure 5e), suggesting that these 
genes may be direct targets of the cleaved histone.  
 
Finally, we propose that HUCA incorporates H3.3 during senescence in a replication-independent 
manner, likely replacing H3.1 at genomic locations including the promoter or regulatory regions of cell-
cycle promoting genes (Figure 6). JARID1A/1B-mediated demethylation and CTSL1-mediated H3.3 tail 
cleavage may cooperate or work independently in the removal of H3K4me3, thus contributing to the 
transcriptional suppression of these genes (Figure 6). Due to the significant overlap between 
JARID1A/1B and H3.3cs1 target genes, histone demethylation and cleavage mechanisms may act 
synergistically at neighboring nucleosomes or at the very same nucleosomes. Furthermore, because 
H3 tail cleavage is a more stable chromatin modification than enzymatic demethylation, the removal of 
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H3K4me3 via histone proteolysis may contribute to long-term repression of proliferation-promoting 
genes and thus, the irreversible nature of senescence. Collectively, our studies have identified a novel 
biological function for the proteolytic cleavage of H3.3 in senescence and we look forward to studies 
that characterize the cleavage of H3 and other histones/histone variants in their respective biological 
contexts.  
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Materials and Methods 
 
Cell culture, plasmids and shRNA - IMR90 fibroblasts were grown in DMEM supplemented with 10% 
FBS and 1% penicillin/streptomycin. Normal human melanocytes were isolated from the epidermis of 
neonatal foreskins and cultured in Melanocyte Growth Media 254 supplemented with Human 
Melanocyte Growth Supplement (Life Technologies). The following retroviral and lentiviral constructs 
were used in this study: pLNCX2-neo (ER::RASV12)19, HIV-CS-CGBRAFE600-puro, and pLL3.7-GFP 
(Addgene). Human full-length and cleaved histone H3 constructs were cloned into the retroviral vector 
pBabe-puro (Addgene) with a C-terminal Flag tag and expressed in IMR90 cells. Point mutations of 
H3.3cs1 were synthesized by Invitrogen (GeneArt) and subsequently cloned into the pBabe vector 
(BamHI-EcoRI). For shRNA studies, IMR90 cells were infected with lentiviral constructs encoding 
CTSL1 shRNAs (Open Biosystems, RHS4533-NM_001912), ASF1a shRNA (The RNAi Consortium 
validated TRCN0000074269) or luciferase shRNA by standard procedures. Infected cells were selected 
using either 1ug/ml puromycin or 800ug/ml neomycin.   
 
Oncogene-induced senescence - Oncogene-induced senescence was performed as described19. 
Briefly, IMR90 human diploid fibroblasts were transduced with a tamoxifen-inducible H-RASV12 
construct (pLNCX2-neo ER::RASV12). A final concentration of 100 nM 4-hydroxytamoxifen (4OHT) was 
used to induce senescence over a 2-week period. Senescence induction with BRAFV600E in 
melanocytes was performed as described6. 
 
CTSL1 inhibition - For CTSL1 inhibition studies, IMR90 ER::RASV12 cells were cultured under growing 
conditions or induced to senesce with 100 nM 4-hydroxytamoxifen in the presence of either DMSO or 
1-5uM CTSL1 inhibitor (Calbiochem, 219421-1MG).  
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Chromatin fractionation, histone acid extraction, MNase digestion and immunoblots - Chromatin 
fractionation was performed as described40. Briefly, cell pellets were resuspended in buffer A (10mM 
Hepes pH=7.9, 10mM KCl, 1.5mM MgCl2, 0.34M sucrose, 10% glycerol, 0.1% triton-X, supplemented 
with protease inhibitor cocktail (Calbiochem, 539131) and 1mM DTT) and incubated on ice for 7-8 
minutes. Nuclei were harvested by centrifugation at 4000 rpm for 5 minutes, and the supernatant 
containing the cytoplasmic fraction was collected. Pelleted nuclei were washed once with triton-free 
Buffer A prior to incubation in No Salt Buffer (3mM EDTA, 0.2mM EGTA, 1mM DTT and protease 
inhibitor) on ice for 40 minutes. The chromatin fraction was recovered by centrifugation at 4000 rpm for 
5 minutes. Supernatant from this last step containing the nuclear soluble fraction was mixed with the 
cytoplasmic fraction to obtain the chromatin-free fraction. Histone acid extraction was performed as 
described41. Micrococcal nuclease treatment was performed as described42. Immunoblots were 
performed with the following antibodies: H3 C-terminus (Millipore, 05-928), H3K4me3 (Millipore, 05-
745), H3K9me3 (Millipore, 07-442), H3K14ac (Millipore, 07-353), H3K18ac (Millipore, 07-354), 
H3K27me3 (Millipore, 07-449), H3K36me2 (Millipore, 07-369), H3.3 (Millipore, 09-838), H4K20me3 
(Millipore, 07-463), H3cs1 (kind gift of Dr. David C. Allis), macroH2A1 (Millipore, 07-219), macroH2A2 
(Bernstein Lab), H2A.Z (Millipore, 07-594), β-Actin (Sigma, A5441), CTSL1 (R & D systems, AF952), 
Flag (Sigma, F7425), MEK2 (BD BioScience, 610235), H-RAS (Santa Cruz Biotechnology, sc-29), p16 
(Santa Cruz Biotechnology, sc-468), p21 (BD BioScience, 556431). 
 
Senescence assays and gene expression - All senescence assays including detection of SA--
galactosidase, EdU incorporation, SAHF, and gene expression changes were performed as 
described14. For colony formation assays, 10,000 cells per condition were plated in 6-well plates and 
grown for 10 days post-selection. Gene expression changes were measured using quantitative RT-
PCR Analysis. Briefly, total RNA was extracted using the RNeasy kit (Qiagen) followed by reverse 
transcription using SuperScript II (Life Technologies). PCRs were performed on a 7500 Fast Real Time 
system (Applied Biosystems) using SYBR Green Master Mix (Roche Applied Science). All values were 
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normalized to GAPDH and relative to the control using the ΔCT method. All quantitative PCRs were 
performed in triplicate. Primer sequences can be found in Supplementary materials. 
 
Nevi collection - Approval to collect benign nevi was granted by the Division of Dermatopathology, 
Icahn School of Medicine at Mount Sinai (project number 08-0964). 
 
Immunofluorescence - Immunofluorescence staining was performed as described previously40. Cells 
were analyzed using the Zeiss, Axio Imager.Z1 or Leica DMI6000B with LAS AF software. Flag 
antibody (Cell Signaling 2368) and H3K9me3 (CMA318, kind gift of Hiroshi Kimura)43 were used for 
staining confocal images of SAHF. 
 
RNA-sequencing - Total RNA samples were isolated using RNeasy kit (Qiagen) and prepared at the 
Icahn School of Medicine at Mount Sinai Genomics Core Facility for poly A library construction and 
sequencing on IlluminaHiSeq 2000. All raw RNA sequencing reads were mapped to the human 
genome (hg19) with TopHat v2.0.344 coupled with Bowtie245 with default parameters. Transcriptomes 
were assembled and fragments per kilo-base per million reads (FPKM) for each gene were computed 
with Cufflinks v2.1.146. Differentially expressed genes were identified using log2 fold change of FPKM 
values for all samples in pair-wise combinations. The cutoff 1.6 was used to determine lists of 
differentially expressed genes, as it produces lists in the hundreds range which is suitable for 
enrichment and overlap analyses. ChIP enrichment analysis was carried out using the ChEA gene-set 
library30 implemented within Enrichr47. The Fisher exact test with the Benjamini-Hochberg correction for 
multiple hypotheses testing was used to perform enrichment analyses. Gene Ontology enrichment 
analysis was carried out using DAVID48 with default parameters. Hierarchical clustering was performed 
using the log2 fold change of the differentially expressed genes in senescence or the H3.3cs1 samples 
vs. the growing control sample using MATLAB (Natick, MA). Venn diagrams were plotted to 
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demonstrate the overlap between the identified differentially expressed genes in this study and 
JARID1A/1B and RB targets as well as H3K4me3 depleted genes during senescence extracted from 
Chicas et al15. The -Log(P) threshold for H3K4me3 depleted genes was set to 4.253 in order to have 
comparable size to the JARID1A/1B target set.  
 
Data deposition - All RNA-Seq data sets have been deposited to NCBI’s Gene Expression Omnibus 
with the deposition number GSE55949. 
 
Native Chromatin Immunoprecipitation - Chromatin from IMR90 cells expressing H3.1FL and H3.3cs1 
was digested with MNase and used for native ChIP using H3K4me3 antibody (Abcam, ab1012), and 
immunoprecipitated DNA was used for qPCR essentially as described42. Primers were designed <1kb 
downstream of the TSS and controls were designed within intergenic regions. Primer sequences can 
be found in Supplementary materials. 
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Figure Legends 
 
Figure 1. Histone H3 tail is processed upon oncogene-induced senescence in fibroblasts and 
melanocytes. (a) Inducible RASV12-driven OIS system in IMR90 fibroblasts evidenced by SA-β-Gal 
staining, DAPI staining to monitor SAHF formation, and EdU incorporation. (b) Immunoblots of growing 
(G) and senescent (S) IMR90s with the indicated histone H3 PTM-specific antibodies. Asterisks 
indicate the proximal cleavage (cs2) and arrows indicate the distal cleavage (cs1). In all panels, core 
histones stained with Amido Black for loading. (c) Immunoblot of the chromatin fraction of senescent 
IMR90s showing alignment of full-length and cleaved histone H3 products. H3cs1-specific antibody 
used for alignment of the distal cleavage product. (d) Diagram of histone H3 tail showing cleavage sites. 
Dashed lines indicate potential proximal cleavage (cs2) sites as determined by immunoblotting with H3 
PTM-specific antibodies. The solid line marks the distal cleavage site (cs1). (e) Immunoblot of growing 
and senescent IMR90 cells with a cleavage-specific antibody (αH3cs1) which recognizes the N-
terminus of H3 beginning at amino acid T2218. (f) IMR90s (G and S) were fractionated into chromatin-
free (cytoplasmic plus nuclear soluble) and chromatin fractions and blotted with the indicated antibodies. 
Mek2 used as a cytoplasmic control and histones/H3 used as chromatin controls. (g) (Left) Bioanalyzer 
trace of chromatin from G and S IMR90s upon MNase digestion and DNA isolation shows 
mononucleosomes. Mononucleosomes were blotted with the indicated antibodies to confirm presence 
of cleaved histone H3 products. (h) Immunoblots of growing and senescent (oncogene-induced and 
replicative senescence) melanocytes with the indicated antibodies (early, middle, late represent 
passages 4, 6 and 8, respectively). Asterisks indicate the proximal cleavage (cs2) and arrows indicate 
the distal cleavage (cs1). (i) Immunoblot of acid-extracted histones from primary growing melanocytes 
(mel) and fresh frozen human benign nevi samples (n=7) with αH3cs1.  
 
Figure 2. Nuclear Cathepsin L mediates H3 tail processing and promotes SAHF. (a) Immunoblot 
for CTSL using whole cell extract from growing and senescent IMR90s. Actin used for loading. (b) (Top) 
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Time course of CTSL1 induction as assessed by RT-qPCR. Values are normalized to expression of 
GAPDH; mean ± s.d. (n=3 biological replicates); p-values as indicated. (Bottom) Immunoblot of the 
chromatin fraction from growing and senescent IMR90 cells with the indicated antibodies. In all panels, 
core histones stained with Amido Black for loading. Samples for RT-qPCR and immunoblot analysis 
were obtained at identical time points. Note correlation of CTSL1 transcriptional induction, presence of 
the active form of CTSL1 in the chromatin fraction and H3 tail cleavage. (c) (Top) Relative expression 
of CTSL1 in growing and senescent melanocytes assessed by RT-qPCR. Values are normalized to 
expression of GAPDH; mean ± s.d. (n=3 technical replicates); p-values as indicated. (Bottom) 
Immunoblot of CTSL using the chromatin fraction of growing and senescent melanocytes. (d) 
Chromatin extracts from growing and senescent IMR90 cells cultured in the presence of DMSO or a 
CTSL1 inhibitor probed with the indicated antibodies. Note the loss of H3 cleavage products in the 
CTSLi-treated cells, particularly at day 8. (e) Chromatin extracts from growing and senescent IMR90 
cells expressing shLuc (control) or shCTSL1 lentiviral constructs probed with the indicated antibodies. 
Note the loss of H3 cleavage products in shCTSL1 senescent cells. (f) Quantification of SAHF in 
growing and senescent IMR90 cultured under the specified conditions obtained at day 8 post-induction; 
mean ± s.d. (n=3 biological replicates); two-tailed unpaired Student’s test; DMSO vs. CTSLi *p=0.0147; 
DMSO vs. shCTSL *p=0.0147.   
 
Figure 3. Ectopic expression of H3.3 and H3.3cs1 induces senescence in fibroblasts. (a) & (b) 
Immunoblot of IMR90 cells stably expressing full length H3.1 (H3.1FL), full length H3.3 (H3.3FL), 
cleaved H3.3 (H3.3cs1) or empty pBabe vector with αFlag. Core histones stained with Amido Black for 
loading. Note the H3 cleavage products in H3.3FL-expressing cells. (c) Quantification of β-Gal positive 
cells in IMR90 cells expressing the indicated histones; mean ± s.d. (n=3 biological replicates) ; p-values 
as indicated. (d) Quantification of EdU incorporation; (n=3 biological replicates); p-values as indicated. 
(e) Quantification of SAHF; mean ± s.d. (n=3 biological replicates); p-values as indicated. (f) (Top) 
DAPI stained nuclei of IMR90s expressing the indicated histones. Images taken at 10X magnification. 
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(Middle) Immunofluorescence of IMR90s expressing the indicated histones stained with DAPI and 
αmacroH2A1. Arrowheads indicate Xi and arrows indicate SAHF. (Bottom). Merged images of DAPI 
and αmacroH2A1. Images taken at 40X magnification (g) Nuclei obtained from IMR90s expressing the 
indicated histones were digested with MNase at 0.16 units per ug of chromatin. DNA was isolated after 
MNase digestion and analyzed by high sensitivity DNA assay (Agilent 2100 Bioanalyzer). (h) Chromatin 
fraction from IMR90 cells expressing pBabe, H3.3FL and H3.3cs1 probed with the indicated antibodies. 
Core histones stained with Amido Black for loading. (i) Colony formation assay course (day 16 post-
infection) of IMR90s expressing the indicated histones. 
 
Figure 4. The histone chaperone complex HUCA is required for chromatin incorporation of 
H3.3cs1. (a) Confocal microscopy of Flag-tagged H3.3FL and H3.3cs1. DAPI, H3K9me3 (red) Flag 
(green) staining, and merged (red and green) images shown. (b) Confirmation of ASF1a and UBN1 
knockdown in IMR90 ER::RASV12 cells by RT-qPCR.  Values are normalized to expression of GAPDH; 
mean ± s.d. (n=2 biological replicates for ASF1a and n=3 technical replicates for UBN1). (c) Chromatin 
fraction from growing and senescent IMR90 ER::RASV12 cells expressing either shLuc, shASF1a or 
shUBN1 probed with αH3cs1. αH-RAS immunoblot shows inducible expression of RASV12. Core 
histones stained with Amido Black for loading. (d) Immunoblot of the chromatin fraction of IMR90 cells 
expressing the indicated histones with αFlag. (e) Representative SA-β-Gal staining images of IMR90 
expressing the indicated histones; quantification shown on the right; mean ± s.d. (n=2 biological 
replicates with 3 technical replicates); p-values as indicated. (f-i) Quantification of EdU incorporation, 
SAHF positive cells, CCNA and p16 levels in IMR90 cells expressing the indicated histones. Values are 
normalized to expression of GAPDH; mean ± s.d. (n=3 technical replicates); p-values as indicated. For 
p16, expression is relative to pBabe control. 
 
Figure 5. H3.3cs1-induced senescence is mediated by decreased transcriptional output of cell 
cycle genes and reduced H3K4me3. (a) Heat map showing gene expression changes of 914 genes 
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as determined by RNA-seq in H3.3cs1-induced senescence (early and late time points) relative to 
those that are altered in OIS (vs. growing). Note the overlap of downregulated genes between H3.3cs1-
induced senescence and OIS. (b) (Top) Venn diagram of genes downregulated in OIS, H3.3cs1 (early) 
and H3.3cs1 (late) as compared to growing IMR90s. Fisher exact test; p= 2.418E-117 OIS vs. H3.3cs1 
(early); p=3.477E-162 OIS vs. H3.3cs1 (late); p=2.404E-117 H3.3cs1 (early) vs. H3.3cs1 (late). (Bottom) 
Venn diagram of genes upregulated in OIS, H3.3cs1 (early) and H3.3cs1 (late) as compared to growing 
IMR90s. Fisher exact test; p=3.414E-4 OIS vs. H3.3cs1 (early); p= 2.883E-7 OIS vs. H3.3cs1 (late); 
p=1.783E-7 H3.3cs1 (early) vs. H3.3cs1 (late). (c) ChIP Enrichment Analysis (ChEA) of H3.3cs1-
induced senescence (top) and OIS (bottom) downregulated genes. Note that E2F family members and 
KDM5B (JARID1B) gene targets are enriched in both. The -log of the p-value associated with each 
term is plotted. (d) Venn diagrams illustrating the overlap between H3.3cs1 downregulated genes and 
genes that lose H3K4me3 in senescence (left) and JARID1A/1B-regulated genes in senescence15. 
Fisher exact test of p values indicated in the diagram. (e) ChIP-qPCR for H3K4me3 at cell cycle genes 
and SASP-related genes in IMR90s expressing H3.1FL (blue) or H3.3cs1 (red). Two regions near the 
GAPDH promoter used as positive controls; intergenic regions used as negative controls. Fold 
enrichment of H3K4me3 ChIP/ Input is plotted. Two-tailed paired sample t-test; p-values as indicated.  
 
Figure 6. Model depicting the mechanisms of H3K4me3 loss in senescence. The HUCA histone 
chaperone complex showing ASF1a/HIRA is depicted depositing H3.3, coupled to eviction of 
replication-dependent histone H3.1. Both JARID1A/1B-mediated demethylation and CTSL-mediated 
proteolytic processing of H3.3 tail act to prevent transcription of cell cycle-related genes via removal of 
H3K4me3. These processes may work together or independently to ensure the silencing of 
proliferation-promoting genes during cellular senescence.  
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